Picture of Nyxoah SA logo

NYXH — Nyxoah SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Belgium's Nyxoah Q3 revenue rises on US commercialization

Belgium's Nyxoah Q3 revenue rises on US commercialization


Overview

  • Belgium medical device maker's Q3 revenue rose sharply yr/yr, driven by U.S. commercialization

  • Q3 gross margin improved to 63.1% from 60.5% a yr ago

  • Operating loss narrowed yr/yr as gross profit rose and R&D expenses fell


Outlook

  • Nyxoah expects 2026 global net revenue of €33 mln to €35 mln

  • Company sees 2026 gross margin between 60% and 62%


Result Drivers

  • U.S. COMMERCIALIZATION - Co said revenue growth was primarily driven by continued expansion of U.S. commercialization activities following FDA approval in August 2025

  • SURGEON TRAINING AND ACCOUNT ACTIVATION - Co cited growing base of trained surgeons and active Genio accounts in the U.S. as supporting momentum

  • OPERATING LEVERAGE - Co attributed improved gross margin to operating leverage on manufacturing-related costs as volumes increase


Company press release: ID:nGNXXKMsx


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

EUR 0.18

Q3 Gross Margin

63.10%

Q3 Gross Profit

EUR 5.79 mln

Q3 Loss Per Basic Share

EUR 0.18


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Nyxoah SA is €4.30, about 461.4% above its November 5 closing price of €0.77


Reuters Recommended Reads

  • Nov 3 - Philips reaches DOJ agreement over device recall, books €288 million provision in Q3

  • Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices

  • Nov 4 - LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Nyxoah SA

See all news